A femto future?

Article

The act of collaboration is generally regarded positively. Uniting two parties that share a common interest usually yields achievements that could not have been possible if either party went at it alone, and so the whole becomes greater than the sum of the parts.

The act of collaboration is generally regarded positively. Uniting two parties that share a common interest usually yields achievements that could not have been possible if either party went at it alone, and so the whole becomes greater than the sum of the parts.

Certainly, this was the thinking behind Schwind and Bausch & Lomb’s recent strategic moves, which resulted in collaborations with established femtosecond laser manufacturers for the two firms. Both companies had already cemented their reputation in the laser refractive surgery market, although one key ingredient was missing from both: the technology that has created a big buzz around the ophthalmology community - the femtosecond laser. The all-LASIK solution that both Schwind and Bausch & Lomb are now able to offer is something that many surgeons and even patients are now requesting.

Despite its growing popularity, the jury is still out on whether femtosecond technology is in fact a must for all refractive surgeons. While many ophthalmologists think that femtosecond technology is the decade’s most significant technological breakthrough, there are those who remain at best undecided and, at the more extreme end of the spectrum, even downright cynical. Particularly in the practice of laser refractive surgery, is a femtosecond laser really such an improvement over a mechanical microkeratome? Some believe not.

Whether refractive surgeons have signed up to the femtosecond fan club or not, today’s refractive surgery practice needs to appear to be at the forefront of technology in order to keep pace in this hugely competitive market. Because of the strong marketing messages and effective advertising campaigns transmitted by some refractive clinics, particularly in the US and Europe, it seems that in order to be, or to be perceived to be, “at the forefront of innovation”, today’s refractive surgery practice needs to jump on the femtosecond bandwagon. Coupled with the expanding indications now being assessed for this technology, there is no way for the femtosecond technology market to go in the next few years other than up.

Best wishes,

Fedra PavlouEditorfpavlou@advanstar.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
© 2025 MJH Life Sciences

All rights reserved.